We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Automatic Cytometer Tallies Tumor Cells in Blood

By LabMedica International staff writers
Posted on 19 May 2015
Flow cytometry has been used to count cancer cells for many years, but the large instruments are expensive and can only be operated by trained personnel.

Existing flow cytometers are capable of measuring the quantity of tumor cells circulating in the bloodstream but they often cost up to EUR 300,000 and can take up a huge amount of space, equivalent to two washing machines. More...


Scientists at the Fraunhofer Institute for Chemical Technology (Munich, Germany) have developed the PoCyton cytometer which is cheap to produce, no bigger than a shoebox, and automated. All the PoCyton flow cytometer needs is a sample of the patient's blood, and within a short time the attending physician will know how many tumor cells are circulating in the blood. Cancerous growths release cells into the bloodstream, and their number provides an indication of how effective the therapy has been. If the number of cancerous cells decreases in the course of treatment, it shows that it has been effective.

Flow cytometry works on the following principle: A fluorescent dye is injected into the blood, and the dye molecules bind to the tumor cells, leaving all other cells unmarked. Whereas until now the physician had to add the dye to the blood sample manually, this now takes place automatically in the PoCyton process. The blood is funneled through a narrow focal area, causing all suspended cells to pass one by one in front of a laser spot detector. The light causes the cells to which the dye has attached itself, the tumor cells, to fluoresce, enabling the device to detect and count them. This narrow passage is the key to the PoCyton process.

Michael Bassler, PhD, a senior scientist who helped develop the cytometer, said, “We designed it in such a way that the throughput is 20 times greater than in conventional cytometry. At the same time, its geometry was chosen to ensure that no cells pass in front of one another. In this way the scientists can be sure that the system registers every single object flowing past the detector, and that no cell is hidden behind another. Such errors could have dramatic consequences, because a mere 10 mL sample of blood contains around one billion suspended objects. Of these, only five are circulating tumor cells, even in a severely sick patient.”

Related Links:

Fraunhofer Institute for Chemical Technology



Gold Member
Neonatal Heel Incision Device
Tenderfoot
Online QC Software
Acusera 24•7
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.